We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Management of Pericarditis in Children.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03253315
Recruitment Status : Unknown
Verified August 2017 by aya gomaa mohamed, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : August 17, 2017
Last Update Posted : August 17, 2017
Information provided by (Responsible Party):
aya gomaa mohamed, Assiut University

Brief Summary:

The pericardium is a double-walled sac containing the heart and the roots of the great vessels. The pericardial sac has two layers, a serous visceral l layer (also known as epicardium when it comes into contact with the myocardium) and a fibrous parietal layer. It encloses the pericardial cavity, which contains pericardial fluid. The pericardium fixes the heart to the mediastinum, gives protection against infection and provides lubrication for the heart. Pericardial diseases may be either isolated disease or part of a systemic disease Diseases of the pericardium present clinically in one of several ways

  • Acute and recurrent pericarditis
  • Pericardial effusion without major hemodynamic compromise
  • Cardiac tamponade with cardiac compromise
  • Constrictive pericarditis

Condition or disease

Detailed Description:
  • Pericarditis usually present with chest pain and dyspnea. Effusion can present with no symptoms, dull ache in left chest and abdominal pain Cardiac tamponade is recognized by the excessive fall of systolic blood pressure
  • Diagnostic workup A) Chest X-ray:_ chest X-ray can detect varying degree of cardiomegaly. B) Echocardiography: It is the first-line imaging test. clinically, two-dimensional echocardiography with Doppler provides the most cost-effective way of diagnosing C) Electrocardiograph D) cardiac computerized tomography :- Also may be helpful 4)Therapy of pericarditis in pediatrics the medical lines of treatment of pericarditis are:_ A)Aspirin and non-steroidal anti-inflammatory:_ are the mainstay of the therapy of inflammatory pericardial diseases B)Steroids: a minority of patients will require treatment with systemic steroid therapy as

    • Patients with symptoms refractory to standard therapy

      • Acute pericarditis due to connective tissue disease ●Uremic pericarditis C)Immunosuppressant and biological drugs (more commonly used in recurrent pericarditis) .Interventional therapeutic techniques-_

Most patients with acute pericarditis can be managed effectively with medical therapy alone. However, patients may require invasive therapies for:

  • A moderate to large pericardial effusion, particularly if hemodynamically significant.
  • Frequent, highly symptomatic recurrences of acute pericarditis with pericardial effusion ●Evidence of constrictive pericarditis (a late occurrence when present) A)Pericardial drainage :Prolonged catheter drainage of a pericardial effusion is an effective means of preventing fluid reaccumulation.

B)Pericardiotomy, pericardial window and pericardiectomy: pericardiectomy may be considered for frequent and highly symptomatic recurrences of pericarditis tamponade .. C)Surgical decompression of the pericardium :_can be achieved either by conventional heart surgery or video-assisted thoracoscopy.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 20 participants
Observational Model: Other
Time Perspective: Other
Target Follow-Up Duration: 15 Days
Official Title: Clinical Audit of the Management of Pericarditis in Children.
Estimated Study Start Date : September 2017
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Echocardiographic signs [ Time Frame: one month ]
    1. normal cardiac size by echocardiography (measurable by echocardiographic probe)
    2. normal thickening of pericardium by echocardiography .(measurable by echocardiographic probe)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients who above one year of age up to 18 years diagnosed with pericarditis and/or pericardial effusions are candidates for the study.

Inclusion Criteria:

  • Children with pericarditis and/or pericardial effusion above one year of age detected clinically and by echocardiography

Exclusion Criteria:

  • children below one year of age. - children with malignant effusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03253315

Layout table for location information
Assiut University
Assiut, Egypt
Contact: nagwa ali, MD    01096260950    namma65@yahoo.com   
Sponsors and Collaborators
Assiut University
Additional Information:

Layout table for additonal information
Responsible Party: aya gomaa mohamed, Principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03253315    
Other Study ID Numbers: ayafadl24791
First Posted: August 17, 2017    Key Record Dates
Last Update Posted: August 17, 2017
Last Verified: August 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Cardiovascular Diseases